柯俊松,杨文学,张鸿宇,黄俊,吕平,陈雲,徐凯

• 1:岳西县医院心内科
• 2:南昌大学第一附属医院心内科

摘要(Abstract)：

目的系统评价生物可吸收支架(BVS)与药物洗脱支架(DES)在治疗急性心肌梗死(AMI)中的安全性和有效性。方法计算机检索Pub Med、Cochrane Library、Embase、Web of Science及相关网站(www.clinicaltrials.gov)。纳入2006年1月至2020年1月关于BVS与DES治疗AMI安全性与有效性的研究。主要有效终点为靶病变血运重建,主要安全终点为明确/可能的支架内血栓形成。由两名研究者按照纳入与排除标准筛选文献,提取资料和评价文献质量。采用Stata 12.0统计软件进行Meta分析。结果最终纳入4个临床研究,其中2个为随机对照研究,2个为观察性研究,共1335例患者,其中BVS组709例,DES组626例。随访时间为12～36个月。Meta分析结果:BVS组与DES组靶病变血运重建(RR 1.59,95%CI0.82～3.10,P=0.337)、明确/可能的支架内血栓形成(RR 1.56,95%CI 0.70～3.46,P=0.685)的差异均无统计学意义。两组靶血管心肌梗死(RR 1.05,95%CI0.41～2.67,P=0.667)、全因死亡(RR 1.35,95%CI 0.52～3.45,P=0.871)、心原性死亡(RR 1.29,95%CI 0.59～2.80,P=0.778)、设备相关的复合终点(RR 1.37,95%CI 0.87～2.16,P=0.425)的差异均无统计学意义。结论 BVS治疗AMI的安全性与有效性可能不劣于DES。

关键词(KeyWords)： 生物可吸收支架;药物洗脱支架;急性心肌梗死;Meta分析

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 柯俊松,杨文学,张鸿宇,黄俊,吕平,陈雲,徐凯

参考文献(References)：

• [1]Zhang YJ,Zhu LL,Bourantas CV,et al.The impact of everolimus versus other rapamycin derivative-eluting stents on clinical outcomes in patients with coronary artery disease:A meta-analysis of 16randomized trials.J Cardiol,2014,64(3):185-193.
• [2]Serruys PW,Garciagarcia HM,Onuma Y.From metallic cages to transient bioresorbable scaff olds:change in paradigm of coronary revascularization in the upcoming decade?Eur Heart J,2012,33(1):16-25.
• [3]陆寒新，Karn SK，车文良，等.生物可吸收支架进展及前景.国际心血管病杂志，2016,43(2):75-78.
• [4]王效增，刘艳杰，郭忱，等.生物可吸收支架置入后影像学随访三年一例.中华心血管病杂志，2019,47(3):235-237.
• [5]Ali ZA,Serruys PW,Kimura T,et al.2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary a rtery disease:a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.Lancet,2017,390(10096):760-772.
• [6]张立博，邓婧，魏向龙.生物可吸收支架在急性冠状动脉综合征中应用的Meta分析.中国介入心脏病学杂志，2018,26(7):390-399.
• [7]Cutlip D E,Windecker S,Mehran R,et al.Clinical end points in coronary stent trials:a case for standardized definitions.Circulation,2007,115(17):2344-2351.
• [8]Higgins JPT,Altman DG,G?tzsche PC,et al.The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.BMJ,2011,343:d5928.
• [9]Peterson J,Welch V,Losos M,et al.The Newcastle-Ottawa scale(NOS) for assessing the quality of nonrandomised studies in metaanalyses.Ottawa:Ottawa Hospital Research Institute,2011.
• [10]Byrne RA,Alfonso F,Schneider S,et al.Prospective,randomized trial of bioresorbable scaffolds vs.everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction:the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial.Eur Heart J,2019,40(2):167-176.
• [11]SabatéM,Windecker S,I?iguez A,et al.Everolimus-eluting bioresorbable stent vs.durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction:results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFIⅡtrial.Eur Heart J,2016,37(3):229-240.
• [12]Katagiri Y,Onuma Y,Asano T,et al.Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaff old and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI IItrial).Euro Intervention,2018,14(11):e1224-e1226.
• [13]Fam JM,Felix C,van Geuns RJ,et al.Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction:a propensitymatched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study.Euro Intervention,2016,12(1):30-37.
• [14]Brugaletta S,Gori T,Low AF,et al.Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction:1-year results of a propensity score matching comparison:the BVS-EXAMINATION Study(bioresorbable vascular scaff old-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).JACC Cardiovasc Interv,2015,8(1 Part B):189-197.
• [15]Brugaletta S,Gori T,Low AF,et al.ABSORB bioresorbable vascular scaff old vs.everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study):2-Year results from a propensity score matched comparison.Int JCardiol,2016,214:483-484.
• [16]Je?ewski MP,Kubisa MJ,Eyileten C,et al.Bioresorbable vascular scaff olds-dead end or still a rough diamond?J Clin Med,2019,8(12):2167.
• [17]Souteyrand G,Amabile N,Mangin L,et al.Mechanisms of stent thrombosis analysed by optical coherence tomography:insights from the national PESTO French registry.Eur Heart J,2016,37(15):1208-1216.
• [18]Ke J,Zhang H,Huang J,et al.Mid-term outcomes of bioresorbable vascular scaff olds vs second-generation drug-eluting stents in patients with acute coronary syndromes:A systematic review and metaanalysis.Medicine,2020,99(10):e19458.
• [19]Everaert B,Wykrzykowska JJ,Koolen J,et al.Recommendations for the use of bioresorbable vascular scaffolds in percutaneous coronary interventions:2017 revision.Neth Heart J,2017,25(7-8):419-428.
• [20]Danzi GB,Bernelli C,Cerrato E.Outcomes of optimised implantation technique with bioresorbable scaffolds:A pooled analysis of ABSORB-Ⅳand COMPARE-ABSORB trials.Cardiovasc Revasc Med,2020,21(4):559-561.
• [21]Puricel S,Cuculi F,Weissner M,et al.Bioresorbable coronary scaff old thrombosis:multicenter comprehensive analysis of clinical presentation,mechanisms,and predictors.J Am Coll Cardiol,2016,67(8):921-931.
• [22]吕续成，沈雳，洪斌，等.生物可吸收支架内血的光学相干断层成像发现及原因分析.中国介入心脏病学杂志，2017,25(10):589-593.
• [23]Ali ZA,Gao RR,Kimura TT,et al.Three-year outcomes with the absorb bioresorbable scaffold:individual-patient-data metaanalysis from the ABSORB randomized trials.Circulation,2017,137(5):464-479.
• [24]Ali ZA,Serruys PW,Kimura T,et al.2-year outcomes with the Absorb bioresorbable scaff old for treatment of coronary artery disease:a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.Lancet,2017,390(10096):760-772.
• [25]Picard F,de Hemptinne Q,Avram R,et al.Bioresorbable vascular scaffold during ST-elevation myocardial infarction:a systematic review.Can J Cardiol,2017,33(4):515-524.
• [26]Goel S,Pasam RT,Chava S,et al.Three to four years outcomes of the absorb bioresorbable vascular scaff old versus second‐generation drug‐eluting stent:A meta‐analysis.Catheter Cardiovasc Interv,2020,95(2):216-223.
• [27]Ielasi A,Campo G,Cortese B,et al.One-year results following a pre-specified ABSORB implantation strategy in ST-elevation myocardial inf arction (BVS STEMI STRATEGY-IT study).Cardiovasc Revasc Med,2019,20(8):700-704.